İn Vitro Fertilizasyon (İVF) Sikluslarında Long Luteal Agonist Tedavisi

Year 2017, Volume: 9 Issue: 1, 1 - 7, 01.03.2017

Bülent Çakmak Mehmet Can Nacar

Abstract

İn vitro fertilizasyon (IVF) sikluslarında daha fazla yumurta
elde etmek için birçok kontrollü overyan hiperstimülasyon (KOH) protokolü bulunmaktadır;
uzun ve kısa agonist protokolleri, tek ve multiple doz antagonist protokolleri
ve agonist+antagonist protokolleri gibi. Bu protokollerden hangisinin daha üstün
olduğu ile ilgili tartışmalar halen devam etmektedir. Ancak şu bir gerçektir ki;
hastanın özelliklerine göre protokol seçimi yapılması elde edilen yeterli sayıda
ve kaliteli yumurta ve  embriyo sağlanması
ve dolayısıyla gebelik şansı artırılmaktadır. Bu yazıda IVF sikluslarında long
luteal agonist protokolü ve diğer protokollerle karşılaştırılması yapıldı.

Keywords

İn vitro fertilizasyon (IVF), gonadotropin serbestleştirici hormon (GnRH), infertilite, protokol.

Long Luteal Agonist Therapy in IVF Cycles

Abstract

There
are several controlled ovarian hyperstimulation (COH) protocols in order to
obtain more eggs in IVFcycles; like long and short agonist protocols, single
and multiple
dose antagonist protocols and agonists antagonist protocols. Debate about which
of theseprotocols is superior is still ongoing. However, it is a
fact;sufficient number and qualified eggs and embryos areobtained by performing
protocol selection according topatient characteristics and hence the chance of
pregnancyis increased. In this paper, the comparison of long luteal phase
agonist protocol and other protocols were made inIVF cycles.

Keywords

In vitro fertilization (IVF), gonadotropin releasing hormone (GnRH), infertility, protocol.

References

• 1. Çalışkan E, Çakıroğlu Y. Kontrollü over hiperstimülasyonu protokolleri. Yardımcı Üreme Teknikleri (Editör: Önder Çelik). Adana. Nobel Kitabevi (Özyurt Matbaacılık). 2011;271-314.
• 2. Carmel PW, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology. 1976;99(1):243-8.
• 3. Özeren M. Kontrollü over uyarısı için kullanılan ilaçlar: klomifen sitrat, aromataz inhibitörleri, gonadotropinler ve gonadotropin serbestleştirici hormon analogları. Yardımla Üreme Teknikleri Temel Kitabı (Çeviri editörleri: Tülay Erez, Oktay Arda, Semih Kaleli). İstanbul. Nobel tıp kitabevleri (Nobel matbaacılık). 2010;519-39.
• 4. Bäckström CT, McNeilly AS, Leask RM, Baird DT. Pulsatile secretion of LH, FSH, prolactin, oestradiol and progesterone during the human menstrual cycle. Clin Endocrinol (Oxf). 1982;17(1):29-42.
• 5. Reame N, Sauder SE, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormonesecretion. J Clin Endocrinol Metab. 1984;59(2):328-37.
• 6. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53-88.
• 7. Knobil E, Hotchkiss J. The menstruel cycle and its neuroendocrine control. In: Knobil E, Neill J, eds. The Physiology of Reproduction. New York: Raven Press, 1988.
• 8. Lemay A, Maheux R, Faure N, Jean C, Fazekas AT. Reversible hypogonadism induced by a luteinizing hormonereleasing hormone (LH-RH) agonist (Buserelin) as a new therapeuticapproach for endometriosis. Fertil Steril. 1984;41(6):863-71.
• 9. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10(8):1974-81.
• 10. Fleming R, Coutts JR. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril. 1986;45(2):226-30.
• 11. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, Schoemaker J. Dosefinding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod. 2000;15(11):2333-40.
• 12. Loumaye E. The control of endogenous secretion of LH by gonadotrophin releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod. 1990;5(4):357-76.
• 13. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788-91.
• 14. Felberbaum RE, Albano C, Ludwig M, Riethmüller-Winzen H, Grigat M, Devroey P, Diedrich K. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod. 2000;15(5):1015-20.
• 15. Fluker M1, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB; North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75(1):38-45.
• 16. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol 2012;10:26.
• 17. Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;1:CD002808.
• 18. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003;80(5):1086-93.
• 19. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310-5.